Software Language Engineering (SLE) is the application of systematic, disciplined, and measurable approaches to the development, use, deployment, and maintenance of software languages. The term “software language” is used broadly, and includes: general-purpose programming languages; domain-specific languages (e.g. BPMN, Simulink, Modelica); modeling and metamodeling languages (e.g. SysML and UML); data models and ontologies (e.g. XML-based and OWL-based languages and vocabularies).
15:30 - 17:00: SLE - DSLs at Regency B
|sle-2017-papers||150876540000015:30 - 15:55|
Xiangqi Li, Matthew FlattDOI
|sle-2017-papers||150876690000015:55 - 16:20|
A Chrestomathy of DSL implementations
Simon Schauss, Ralf Lämmel, Johannes Härtel, Marcel Heinz, Kevin Klein, Lukas Härtel, Thorsten BergerDOI
|sle-2017-papers||150876840000016:20 - 16:45|
Ankica Barisic, Dominique Blouin, Vasco Amaral, Miguel GoulaoDOI
|sle-2017-papers||150876990000016:45 - 17:10|
Better Call the Crowd. Using Crowdsourcing to Shape the Notation of Domain-Specific Languages
Marco Brambilla, Jordi Cabot, Javier Luis Cánovas Izquierdo, Andrea MauriDOI
15:30 - 17:00: SLE - GPL/DSL implementation at Regency B
|sle-2017-papers||150885180000015:30 - 15:55|
FlowSpec: Declarative Dataflow Analysis Specification
Jeff Smits, Eelco VisserDOI File Attached
|sle-2017-papers||150885330000015:55 - 16:20|
Metacasanova: An Optimized Meta-compiler for Domain-Specific Languages
Francesco Di Giacomo, Mohamed Abbadi, Agostino Cortesi, Pieter Spronck, Giuseppe MaggioreDOI
|sle-2017-papers||150885480000016:20 - 16:45|
Jiasi Shen, Martin RinardDOI
|sle-2017-papers||150885630000016:45 - 17:10|
An Introduction to the Software Language Engineering Body of Knowledge
|sle-2017-papers|| - |
Energy Efficiency across Programming Languages: How do Energy, Time, and Memory Relate?
Rui Pereira, Marco Couto, Francisco Ribeiro, Rui Rua, Jácome Cunha, João Paulo Fernandes, João SaraivaDOI Media Attached
Summaries for consumers
Dehydroepiandrosterone (DHEA) for lupus erythematosus
DHEA probably leads to little or no difference in disease activity in people with mild to moderate disease, but probably slightly improves overall well‐being. These results are based on moderate quality evidence.
Cyclophosphamide versus methylprednisolone for lupus
Researchers in The Cochrane Collaboration conducted a review of the effect of cyclophosphamide for people with central nervous system lupus compared to the usual treatment of methylprednisolone. After searching for all relevant studies, they found one study with 32 people. The study compared people who took cyclophosphamide by IV (intravenous or through a vein) to people who took steroids (methylprednisolone by IV). All people took steroid pills (prednisone) at the beginning of the study and the amount was decreased over the study. The study lasted two years.
Treatment for people with lupus nephritis
Lupus nephritis is an inflammatory condition affecting the kidneys which is caused by systemic lupus erythematosus (SLE), an autoimmune disease that is more common among women. About half of all people with SLE develop lupus nephritis, and of these about 1/10 experience chronic kidney disease or kidney failure. Treatment aims to delay disease progression and achieve remission by stabilising and improving kidney function and minimising side effects. For about the past 30 years, standard treatment for lupus nephritis has focused on a combination of cyclophosphamide (an alkylating agent) and corticosteroids.
See all (9)